NVS Novartis AG
- 97.715
- +0.275+0.28%
Novartis AG News
Impacted by reports of drug safety issues, Morphosys (MOR.US) says the Novartis Pharmaceuticals (NVS.US) acquisition will continue as planned
The Zhitong Finance App learned that on Monday, the stock price of German biotech company Morphosys (MOR.US) fell due to a news report about its drugs or safety risks, but Morphosys said that Novartis Pharmaceuticals (NVS.US) is still expected to complete its acquisition in the first half of this year. Prior to Morphosys' statement, the professional website StatNews quoted two people familiar with the matter as reporting that the company is developing an experimental drug pelabresib to treat myelofibrosis (a rare type of blood cancer affecting bone marrow)
New Safety Risk for MorphoSys Drug Could Complicate Novartis Deal - STAT
A new safety risk related to Morphosys's (NASDAQ:MOR) pelabresib, an experimental treatment for myelofibrosis, could complicate the company's planned $3B sale to Novartis (NYSE:NVS).
J&J, Roche, AstraZeneca Poised to Have Highest Orphan Drug Sales by End of Decade
Express News | Novartis innovates PNH oral monotherapy Feheda (ipcopam hydrochloride capsules) approved in China
Express News | Novartis's innovative drug for rare diseases has been approved domestically. It is the first oral monotherapy for PNH treatment in adults
Pharma Stock Roundup: MRK, SNY, AZN, NVS' Q1 Results, Pipeline & Regulatory Updates
Express News | Novartis innovates PNH oral monotherapy ipcopam hydrochloride capsules approved in China
Novartis Pharms Corp Gets FDA New Drug Application Approval For VIJOICE
Novartis Pharms Corp Gets FDA New Drug Application Approval For VIJOICE
Analysts Have Conflicting Sentiments on These Healthcare Companies: Carl Zeiss Meditec (GB:0DHC), Siemens Healthineers AG (OtherSEMHF) and Novartis AG (Six Swiss: CH:NOVN)
BMO Capital Maintains Market Perform on Novartis, Raises Price Target to $116
BMO Capital analyst Etzer Darout maintains Novartis with a Market Perform and raises the price target from $114 to $116.
Novartis Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/24/2024 18.77% BMO Capital $114 → $116 Maintains Market Perform 02/23/2024 16.72% BMO Capital → $114 In
Company News for Apr 24, 2024
Novartis And Medicines For Malaria Venture Announced Data From Phase 2/3 CALINA Study, Demonstrating That Formulated Coartem Developed For Babies Weighing Less Than 5Kg With Malaria Has The Required Pharmacokinetic Profile, Good Efficacy, And Safety
Novartis And Medicines For Malaria Venture Announced Data From Phase 2/3 CALINA Study, Demonstrating That Formulated Coartem Developed For Babies Weighing Less Than 5Kg With Malaria Has The Required P
Analysts Have Conflicting Sentiments on These Healthcare Companies: Alcidion Group Limited (ALC) and Novartis AG (Six Swiss: CH:NOVN)
Novartis Partnership Says New Malaria Drug for Babies Effective, Safe in Phase 2/3 Trial
Novartis (NOVN.SW) and the product development partnership Medicines for Malaria Venture on Wednesday said a new formula of malaria drug Coartem for babies showed "good" efficacy and safety in the pha
Express News | Novartis Pharmaceuticals CALINA antimalarial research data is positive.
Novartis Receives FDA Approval for Gastroenteropancreatic Tumor Treatment in Pediatric Patients
Novartis (NOVN.SW) received approval from the US Food and Drug Administration for its radioligand therapy Lutathera for pediatric patients aged 12 years and older with gastroenteropancreatic neuroendocrine tumors.
US Equity Markets Close Higher Tuesday
US equity markets ended higher Tuesday as investors assessed the latest batch of corporate earnings. * New-home sales rose to a 693,000 annual rate in March from a downwardly revised 637,000 rate in F
Novartis Radioligand Therapy Lutathera FDA Approved First Medicine Specifically For Pediatric Patients With Gastroenteropancreatic Neuroendocrine Tumors
Approval based on NETTER-P trial in which Lutathera demonstrated a consistent safety profile and comparable drug exposure between pediatric (ages 12-17) and adult patients Gastroenteropancreatic neuro
Novartis Wins Pediatric Indication for Lutathera for Rare Cancer
Analysis
Price Target
No Data
